Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre

BACKGROUND: Regorafenib is a multi-kinase inhibitor approved as third line treatment for metastatic GIST. Dose limiting toxicities are frequently seen and many patients require dose reductions. This study aimed to evaluate regorafenib toxicities and their management in a real-world GIST population....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Sarcoma Res
Hlavní autoři: Chamberlain, Florence, Farag, Sheima, Williams-Sharkey, Constance, Collingwood, Cecilia, Chen, Lucia, Mansukhani, Sonia, Engelmann, Bodil, Al-Muderis, Omar, Chauhan, Dharmisha, Thway, Khin, Fisher, Cyril, Jones, Robin L., Gennatas, Spyridon, Benson, Charlotte
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6942401/
https://ncbi.nlm.nih.gov/pubmed/31911828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-019-0123-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky